Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, +758

The Lancet

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, +359

The Lancet

VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report +5

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, +758

The Lancet

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer, +43

Nature Medicine

VaccinationVaccine DevelopmentAllergyImmunologyImmunodominance +10

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, +29

reponame:Expeditio Repositorio Institucional UJTL

VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report +5

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Mehreen S. Datoo, Hamtandi Magloire Natama, Ousmane Traoré, +32

The Lancet

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold, +51

Nature Medicine

VaccinationPhase 1/2Vaccine DevelopmentImmunologyHumoral Immunity +5

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Mehreen S. Datoo, Hamtandi Magloire Natama, Duncan Bellamy, +29

The Lancet Infectious Diseases

VaccinationClinical MalariaBurkina FasoMalariaImmunology +6

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin, +184

The Lancet

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Pedro M. Folegatti, Mustapha Bittaye, Amy Flaxman, +27

The Lancet Infectious Diseases